Last reviewed · How we verify
Tirosint®-SOL
Tirosint-SOL is a liquid formulation of levothyroxine that replaces deficient thyroid hormone to restore normal thyroid function.
Tirosint-SOL is a liquid formulation of levothyroxine that replaces deficient thyroid hormone to restore normal thyroid function. Used for Hypothyroidism (replacement therapy), Thyroid cancer suppression therapy, Myxedema coma.
At a glance
| Generic name | Tirosint®-SOL |
|---|---|
| Also known as | levothyroxine sodium oral solution (liquid) |
| Sponsor | IBSA Institut Biochimique SA |
| Drug class | Thyroid hormone replacement |
| Target | Thyroid hormone receptors (TR-alpha and TR-beta) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Levothyroxine is a synthetic form of thyroxine (T4), a thyroid hormone that is converted peripherally to the active T3 form. It binds to thyroid hormone receptors throughout the body to regulate metabolism, energy production, and growth. The liquid formulation (SOL) provides improved bioavailability and more consistent absorption compared to tablet formulations, particularly in patients with malabsorption issues or those taking concurrent medications that interfere with absorption.
Approved indications
- Hypothyroidism (replacement therapy)
- Thyroid cancer suppression therapy
- Myxedema coma
Common side effects
- Tremor
- Tachycardia
- Palpitations
- Anxiety
- Insomnia
- Heat intolerance
- Weight loss
Key clinical trials
- Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH) (PHASE4)
- Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tirosint®-SOL CI brief — competitive landscape report
- Tirosint®-SOL updates RSS · CI watch RSS
- IBSA Institut Biochimique SA portfolio CI